A quantitative study of tumor response and progression-free survival as surrogate endpoints for overall survival in first-line treatment of metastatic breast cancer

被引：0
|
作者：
Burzykowski, T
Piccart, MJ
Sledge, G
Carmichael, J
Luck, HJ
Mackey, JR
Nabholtz, JM
Paridaens, R
Biganzoli, L
Jassem, J
Blohmer, JU
Bontenbal, M
Bonneterre, J
Chan, S
Atalay, G
Therasse, P
Buyse, M
机构：
[1] Limburgs Univ Centrum, Diepenbeek, Belgium
[2] Inst Jules Bordet, B-1000 Brussels, Belgium
[3] IDDI, Brussels, Belgium
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2005年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S277 / S278
页数：2
相关论文
共 50 条
  • [31] Lenvatinib as first-line treatment for advanced thyroid cancer: long progression-free survival
    De Leo, Simone
    Di Stefano, Marta
    Persani, Luca
    Fugazzola, Laura
    Colombo, Carla
    ENDOCRINE, 2021, 72 (02) : 462 - 469
  • [32] Progression-Free Survival as a Surrogate Endpoint of Overall Survival in Patients With Metastatic Renal Cell Carcinoma
    Halabi, Susan
    Rini, Brian
    Escudier, Bernard
    Stadler, Walter M.
    Small, Eric J.
    CANCER, 2014, 120 (01) : 52 - 60
  • [33] Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer
    Burzykowski, Tomasz
    Buyse, Marc
    Piccart-Gebhart, Martine J.
    Sledge, George
    Carmichael, James
    Lueck, Hans-Joachim
    Mackey, John R.
    Nabholtz, Jean-Marc
    Paridaens, Robert
    Biganzoli, Laura
    Jassem, Jacek
    Bontenbal, Marijke
    Bonneterre, Jacques
    Chan, Stephen
    Basaran, Gul Atalay
    Therasse, Patrick
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (12) : 1987 - 1992
  • [34] INVESTIGATING PROGRESSION-FREE SURVIVAL AS A POTENTIAL SURROGATE ENDPOINT FOR OVERALL SURVIVAL IN FIRST-LINE TREATMENT FOR GLIOBLASTOMA MULTIFORME: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
    Fu, A.
    Fazeli, M. S.
    Kanters, S.
    Siliman, G.
    Ma, Chaudhary
    Gogate, A.
    Kurt, M.
    VALUE IN HEALTH, 2020, 23 : S4 - S4
  • [35] Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer
    Foster, Nathan R.
    Renfro, Lindsay A.
    Schild, Steven E.
    Redman, Mary W.
    Wang, Xiaofei F.
    Dahlberg, Suzanne E.
    Ding, Keyue
    Bradbury, Penelope A.
    Ramalingam, Suresh S.
    Gandara, David R.
    Shibata, Taro
    Saijo, Nagahiro
    Vokes, Everett E.
    Adjei, Alex A.
    Mandrekar, Sumithra J.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (07) : 1099 - 1106
  • [36] Effects of taxanes alone or in combination with anthracyclines on tumor response, progression-free survival and overall survival in first-line chemotherapy of patients with metastatic breast cancer: an analysis of 4,256 patients randomized in 12 trials
    Piccart, MJ
    Burzykowski, T
    Sledge, G
    Carmichael, J
    Luck, HJ
    Mackey, JR
    Nabholtz, JM
    Paridaens, R
    Biganzoli, L
    Jassem, J
    Blohmer, JU
    Bontenbal, M
    Bonneterre, J
    Chan, S
    Atalay, G
    Therasse, P
    Buyse, M
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S278 - S279
  • [37] Prolonged progression-free survival in metastatic breast cancer
    Mayor, Susan
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2008, 69 (07) : 378 - 378
  • [38] Improved progression-free survival in metastatic breast cancer
    Burki, Talha Khan
    LANCET ONCOLOGY, 2018, 19 (02): : E79 - E79
  • [39] APPLICATION OF PROGRESSION-FREE SURVIVAL AS SURROGATE ENDPOINT FOR OVERALL SURVIVAL IN NICE REVIEWS OF ADVANCED BREAST CANCER DRUGS
    Zou, D.
    Sun, A.
    Musci, R.
    Milev, S.
    VALUE IN HEALTH, 2022, 25 (01) : S183 - S184
  • [40] Progression-Free Survival as a Surrogate Marker of Overall Survival Is It the Good Question?
    Escudier, Bernard
    CANCER, 2011, 117 (12) : 2586 - 2587
12345